Clinical Trials Logo

Filter by:
NCT ID: NCT04835909 Recruiting - Clinical trials for Cognitive Impairment, Mild

Board Games Among Mild Cognitive Impairment Patients Experience (GAME Project)

GAME-Project
Start date: February 16, 2021
Phase: N/A
Study type: Interventional

Nowadays, on geriatric centres, cognitive decline used to be prevented by pen and paper exercises (Calero García & Navarro Gonzalez, 2006). However, as Lampit et al. (2014) suggest, studies based on the efficacy and effectiveness of new cognitive-based interventions in order to improve these cognitive processes are fundamental (Lampit et al., 2014). Cognitive-based interventions are interventions that directly or indirectly try to improve cognitive processes (Chiu et al., 2017). Between the different kinds of cognitive-based interventions, cognitive training permits stablish randomized controlled trials. Cognitive training consists of repeating during a concrete time a standardized set of tasks in order to maintain or improve one or some cognitive processes. Meta-analysis studies have shown that computerized cognitive training can improve in a moderate size some cognitive processes in elderly people with mild cognitive impairment or dementia (Hill et al., 2017) and without those diagnoses (Lampit, Hallock, & Valenzuela, 2014; Chiu et al., 2017). Although it seems that computerized training is effective, safe and secure, it is important to note the social component of the definition of health (OMS, 1948). Chang, Wray & Lin (2014) found that social relationships predict the use of leisure activities and this predict a better physical health and wellbeing psychological. In fact, a comparative study found that those elderly people that have played board games have a 15% lower risk of having dementia diagnose and problems related with memory (Dartigues et al., 2013). To sum up, the aim of this research project is to test the effectiveness of a cognitive training based on modern board and card games in elderly people with a diagnose of mild-cognitive impairment in comparison to do cognitive paper and pencil tasks or in a wait-list comparison group.

NCT ID: NCT04835584 Recruiting - Clinical trials for Chronic Myeloid Leukemia

KRT-232 and TKI Study in Chronic Myeloid Leukemia

Start date: May 7, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.

NCT ID: NCT04834466 Recruiting - Pain Clinical Trials

Factors Associated With Pain Level Experience in Orthodontic Treatment

Start date: February 4, 2021
Phase:
Study type: Observational

Orthodontic pain has been the primary concern from all patients who requires orthodontic treatment. The design of the study will help us comprehend how patient experienced and managed pain during their orthodontic treatment, average pain level in different orthodontic appliances and factors that could affect pain level experience during treatment, including gender, age, brackets types, hygiene level and habitude.

NCT ID: NCT04833894 Recruiting - Clinical trials for Generalized Myasthenia Gravis

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

Start date: October 26, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG. Trial details include: - The maximum trial duration for each individual participant will be approximately 28 weeks - The treatment duration will be 8 weeks for the dose-confirmatory part (Part A) and 18 weeks for the treatment response-confirmatory part (Part B)

NCT ID: NCT04833322 Recruiting - Refractory Epilepsy Clinical Trials

Galactose Supplementation for the Treatment of MOGHE

GATE
Start date: January 15, 2021
Phase: N/A
Study type: Interventional

Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE) is a new entity frequently associated with refractory epilepsy and neurodevelopmental disorders. Recently, it has been associated to SLC35A2 (Solute Carrier Family 35 Member A2) brain mosaic pathogenic variants. In addition, patients with germline SLC35A2 pathogenic variants improve with galactose supplementation. Therefore, the investigators aim to elucidate whether d-galactose as an add-on treatment might improve epilepsy and developmental outcomes in patients with MOGHE.

NCT ID: NCT04833114 Recruiting - Clinical trials for Refractory Diffuse Large B-Cell Lymphoma

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Pola-R-ICE
Start date: April 30, 2021
Phase: Phase 3
Study type: Interventional

An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)

NCT ID: NCT04832607 Recruiting - Clinical trials for Stem Cell Transplant Complications

Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

TRACE
Start date: August 27, 2019
Phase: Phase 3
Study type: Interventional

Haematopoietic stem cell transplantation (HSCT) can expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality. Adoptive transfer of virus-specific T cells is an attractive approach to restore protective T-cell immunity in patients with refractory viral infections after allogeneic HSCT. The aim of this Phase III trial is to confirm efficacy of this treatment in children and adults.

NCT ID: NCT04831125 Recruiting - Heart Failure Clinical Trials

Conduction System Pacing International Registry (CONSPIRE)

Start date: April 4, 2021
Phase:
Study type: Observational [Patient Registry]

The purpose of this registry study is to collect information about routine clinical practices with device implantation to treat bradycardia and cardiac systolic dysfunction (heart rhythm disorders) across global centers of excellence in cardiac pacing. In particular, this study will examine the use of conduction system pacing (CSP) in clinical practice. Information collected in the registry will help researchers better characterize strengths and limitations of current technology and treatments.

NCT ID: NCT04831086 Recruiting - Preterm Birth Clinical Trials

To Optimize Antenatal Management of Women With Pre Term Labor Using Amniocentesis

OPTIM-PTL
Start date: May 5, 2021
Phase: Phase 3
Study type: Interventional

Implementation of prediction models of risk of spontaneous delivery within 7 days or of intra-amniotic infection in women with preterm labor and intact membranes

NCT ID: NCT04830124 Recruiting - Cutaneous Melanoma Clinical Trials

Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6

ARTISTRY-6
Start date: May 27, 2021
Phase: Phase 2
Study type: Interventional

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma following prior anti-PD-[L]-1 therapy